<SEC-DOCUMENT>0001193125-25-192215.txt : 20250829
<SEC-HEADER>0001193125-25-192215.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250829103603
ACCESSION NUMBER:		0001193125-25-192215
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20250829
FILED AS OF DATE:		20250829
DATE AS OF CHANGE:		20250829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		251277347

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d86864d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:22pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of August 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#8217;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;Form <FONT
STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In August 2025, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated
herein by reference. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:22pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><U>Exhibit&nbsp;No.</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>Description</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><A HREF="d86864dex991.htm">Press Release dated August&nbsp;14, 2025: Sanofi&#8217;s rilzabrutinib earns orphan designation in the EU for IgG4-related disease. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: August&nbsp;29, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By&#8195;&#8194;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>/s/ <U>Alexandra Roger&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d86864dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:14pt; font-family:Verdana"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">


<IMG SRC="g86864g90z17.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Georgia"><FONT COLOR="#7900e6"><I>Sanofi&#8217;s rilzabrutinib earns orphan designation in the EU for IgG4-related disease </I></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt">Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at
EULAR 2025 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Verdana; font-size:11pt">Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><B>Paris, August</B><B></B><B>&nbsp;14, 2025. </B>The European Medicines Agency has granted orphan designation to
rilzabrutinib, a reversible covalent Bruton&#8217;s tyrosine kinase (BTK) inhibitor, for IgG4-related disease <FONT STYLE="white-space:nowrap">(IgG4-RD).</FONT> EMA grants orphan designation to investigational therapies addressing rare,
life-threatening or debilitating medical diseases or conditions that affect no more than 5 in 10,000 persons in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Rilzabrutinib for the
treatment of IgG4-related disease was evaluated in a phase 2 study (clinical study identifier: <FONT STYLE="font-family:Verdana; font-size:10pt" COLOR="#7a00e6"><U>NCT04520451</U></FONT><FONT STYLE="font-family:Verdana">) and results were presented
at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress. In <FONT STYLE="white-space:nowrap">IgG4-RD</FONT> patients, treatment with rilzabrutinib for 52 weeks led to reduction in disease flare, other disease markers, and
glucocorticoid sparing. The safety profile of rilzabrutinib in the study was consistent with previous studies, with no new safety signals observed. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">In addition to IgG4-related disease, rilzabrutinib has received orphan designations for immune thrombocytopenia (ITP) in the US, the EU, and Japan;
and for&nbsp;<FONT STYLE="font-family:Verdana; font-size:10pt" COLOR="#7a00e6"><U>warm autoimmune hemolytic anemia</U></FONT><FONT STYLE="font-family:Verdana">, </FONT><FONT STYLE="font-family:Verdana; font-size:10pt" COLOR="#7a00e6"><U><FONT
STYLE="white-space:nowrap">IgG4-RD</FONT></U></FONT><FONT STYLE="font-family:Verdana"> and </FONT><FONT STYLE="font-family:Verdana; font-size:10pt" COLOR="#7a00e6"><U>sickle cell disease</U></FONT><FONT STYLE="font-family:Verdana"> in the US.
Rilzabrutinib has also been granted fast track designation in the US in ITP and <FONT STYLE="white-space:nowrap">IgG4-RD.</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Rilzabrutinib is currently under regulatory review in the US, the EU, and China for its potential use in ITP. The target action date for the US FDA
regulatory decision for ITP, which was granted fast track designation, is August&nbsp;29, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Rilzabrutinib is an investigational agent, and
its safety and efficacy have not been evaluated by any regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About rilzabrutinib </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Rilzabrutinib is a novel, advanced, oral, reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare
immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and
inflammatory pathways. With the application of the TAILORED COVALENCY<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of <FONT
STYLE="white-space:nowrap">off-target</FONT> side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About <FONT STYLE="white-space:nowrap">IgG4-RD</FONT>
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><FONT STYLE="white-space:nowrap">IgG4-RD</FONT> is a progressive, relapsing, chronic immune-mediated rare disease, which can manifest
in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes-fatal outcome. People with <FONT STYLE="white-space:nowrap">IgG4-RD</FONT> experience frequent <FONT STYLE="white-space:nowrap">flare-ups</FONT> of the
condition characterized by periods of exacerbated symptoms. It affects approximately eight out of 100,000 adult patients in the US each year. Due to its rarity and challenges with diagnosis, the global prevalence of
<FONT STYLE="white-space:nowrap">IgG4-RD</FONT> is unknown. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi is an R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#8217;s lives and
delivering compelling growth. We apply our deep understanding of the immune system to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g86864g75o58.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">
invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.&nbsp;Our team is guided by one purpose: we
chase the miracles of science to improve people&#8217;s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal
challenges of our time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Sandrine Guendoul</B> | +33 6 25 09 14 25 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Evan Berland</B> | +1 215 432 0234 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>L&eacute;o Le Bourhis</B> | +33 6 75 06 43 81 | <FONT
STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Victor Rouault</B> | +33 6 70 93 71 40 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Timothy Gilbert</B> | +1 516 521 2929 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>L&eacute;a Ubaldi</B><B></B>&nbsp;| +33 6 30 19 66 46
|&nbsp;<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>lea.ubaldi@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Thomas Kudsk Larsen</B> |+44 7545 513 693 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Aliz&eacute; Kaisserian </B>| +33 6 47 04 12 11 | <FONT
STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Felix Lauscher </B>| +1 908 612 7239 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Keita Browne </B>| +1 781 249 1766 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Nathalie Pham </B>| +33 7 85 93 30 17 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Tarik Elgoutni </B>| +1 617 710 3587 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Thibaud Ch&acirc;telet</B> | +33 6 80 80 89 90 |
<FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:Verdana"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana" ALIGN="justify"><B>Yun Li</B> | +33 6 84 00 90 72 | <FONT STYLE="font-family:Verdana; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT
STYLE="font-family:Verdana"> </FONT></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify"><B>Sanofi forward-looking statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify"><I>This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future
financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;,
&#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221; and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the
future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual
property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes
thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks
and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking
Statements&#8221; in Sanofi&#8217;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise
any forward-looking information or statements. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:Verdana" ALIGN="justify"><I>All trademarks mentioned in this press release are the property of the Sanofi group.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g86864g75o58.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g86864g75o58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g86864g75o58.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0,<17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    7   !5H=I  0    !   !;IR=  $    N   "YNH<
M  <   $,    2@     <Z@    $
M
M
M
M
M
M                5&AI>6%G87)O;W!A;B!%;'5M86QA:0    60 P "
M%    KR0!  "    %    M"2D0 "     S8Q  "2D@ "     S8Q  #J'  '
M   !#    ;      '.H    !
M
M
M
M
M
M             #(P,C4Z,#@Z,C@@,C,Z,S@Z-#@ ,C R-3HP.#HR." R,SHS
M.#HT.    %0 : !I 'D 80!G &$ <@!O &\ < !A &X ( !% &P =0!M &$
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M(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $,
M @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*
M#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
M !$( !\ 3 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&
M!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U
M$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@ , P$  A$#$0 _ /W\HJKJ$Z6ZLTCK&B(79F8*$4=6YXXZDGI7Q?\ M _\
M' '[,?[-/Q;U#P-XA\97EUKNCS&UU--*TJXO+?39U8(T,DJKM9@V00FXC'2B
MZ ^VJ*\+U[_@H;\%_#O[+-I\;K[QWIMM\,=1B\RRUJ6*=%NF,CQ!(X602F3>
MC+M50W'(QS7D/[.W_!?3]F']I_XK:7X+\-^.;ZW\1:_=1V&EVFH:%>6_VZX>
M0(B*YC*!BQ'#%>HY[4 ?:5%?&O[3_P#P7=_9I_9&^+&I^!_%GC:^/BC19!!J
M5E8:->7*V$@4-L>18_+#8(.U"3R*]>_9V_;^^$O[5/P(OOB7X,\9Z5J'@S1Q
M(VJWUP&L_P"R3&BR.+E)=K0E8R&PXY&,&@#VRBOA[P)_P<-?LH?$#XLVOA"Q
M^)1AO+RY-G;:C>:1=V^FW,VXIM$\B *"P(#MA&[,<<?/'_!?_P#X*.^)?@I\
M?_AE\&K#QU:_#'P)XUTO^V?%/BJ'0DUR[AMC.ZQK% 5?(!@)&P9)9?G6C2^H
M'ZT;J*_-O]D_X_\ AG_AI?\ 9D\*Z7\=)_%LGB#P)>7VGV-QX)?3I/%<):_D
M^UF018LQ^X/[MB#BUQ@^>"?T@MSE6Z_>(Y[XXK2I34=G<IJQSOQ=LM/U+X:>
M(K?5KO\ L_2;C2[F*]N@VW[-"T;!Y,X.-JY.>W7M7XQ^#?A'\8OV(?%'QV^(
MW[/=Q\*?VB/@IJVNWNI>*_#>M6$D>K6'E[Y98V\Y5>;;$Q"R(TD<FUV\IB#G
M]N-4L8=5MI+6XCCG@N$,<L4B[E=6!!!![$9&/>N=T#X4>%_">D:II.G^&] T
M_3M>DDDU"TMM/BA@OWE4+,TJ*N)"RX#%LY  Z"E'E4+=23\5?^"B_P"TKX-_
M:H_8P_8M^,>D^ _^$=^ ?@WQ\+/QMX5L+0/::.(Y[=3:B.)%CDB,<-TJLJ -
MYJK@&4BM#]N[]J[X+_M4_P#!7K]BFZ^#>O\ A_Q!:Z+XCM(K_P#LBS-L+</?
MVK1*^40@".-_EQP,<^G[,:!\#_!GAOX<OX/T_P '^%]/\)R*T<FB6NE00Z:5
M;YG4VZKY9!)R1M.37._#+]CWX1? C6/[2\%_"_X<^#[Z1L"YT;PU9V$Q)]'A
MC4CGN<U 'P#_ ,$P/"^F^(?^"VO[<']H:=9ZAY=]8*GVF!95C!,N50'^]CD_
M],Z^0?"WPI\1>*/V(?\ @IAX:^'MC,9-/^(ZM'IFG0DD6%MJT[S11HIP1]GB
M(9<?,L;#GC'[Q>'?@_X5\(^,-8U[2?#>@Z7K^O;6U74[+3H;>]U(C[IFF10\
MFWG[Q/4\4WP9\*O"OPVU'5]0\-^&M \/W&O7'VO5)].L(K634IFY\R9D0&1_
MF)W-D\]: /Q*_;"_;?\ V5/BQ_P0C\,?#'P2FCWOQ+DTO0M-TO0+'2'75K#5
M(IK<7<OF>3]\[)PTF?WOF?[==C\0O!FO>$?^"Q/_  3U\/\ C2/S?$VE_"S2
M['6H[A"V+R*UODG!SU82*V3WZ]Z_5[PY^QC\(?"OQ';QAI/PK^'.F>+/,:0Z
MW:^&[*#4=Y)W/YZQ;RQ.3DM72:W\(_"/BCQ]I?BK4O"_AS4/%&E1F+2]8NM,
MAFU*P3YB4BG=2\8RS'Y6 ^8\=R>HT?G1^U#:1V/_  ='_LN0PQI%''\.M154
M4851]FU_BOU#C^[_ )]*Y;5_A)X5UGXC:?XJNO#/A^Z\7:5;/:V.LRZ?"VI6
CD#[MZ17!4O&IWOE58 [VXY.>GM5VPCWY)QC/OCWHZW"Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g86864g90z17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g86864g90z17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+$17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    7   !5H=I  0    !   !;IR=  $    N   "CNH<
M  <   $,    2@     <Z@    $
M
M
M
M
M
M                5&AI>6%G87)O;W!A;B!%;'5M86QA:0    'J'  '   !
M#    8      '.H    !
M
M
M
M
M
M            5 !H &D >0!A &< 80!R &\ ;P!P &$ ;@ @ $4 ; !U &T
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M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MK_8R\-PZM\3/&^A^$;>X)%M%>2DW%UCJ(X4#2/ZG:IP,DX ) !ZM17Y^VO\
MP<T_LD7.NI8GQEX@AA9MHO)/#UVMOZ9!V[R/HIKZX_9Q_:W^&W[7/AG^VOAK
MXW\/^,=.A.)FT^X#20''22(D21G_ 'U% 'H]RVR!B1N '(QG/X5^77_!5?\
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<[L[ZRT$7LVHLMY=-<327$F!([,?78M>P4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
